Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study

Gabor Liposits, Henrik Eshoj, Sören Möller, Stine Braendegaard Winther, Halla Skuladottir, Jesper Ryg, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Åke Berglund, Camilla Qvortrup, Pia Österlund, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review


Quality of life data from randomized trials are lacking in older patients with metastatic colorectal cancer (mCRC). In the randomized NORDIC9-study, reduced-dose S1+oxaliplatin (SOx) showed superior efficacy compared to full-dose S1 monotherapy. We hypothesized that treatment with SOx does not result in inferior quality of life. Patients with mCRC aged ≥ 70 years and that were not a candidate for standard combination chemotherapy were included and randomly as-signed to receive either S1 or SOx. The EORTC QLQ-C30 questionnaire was completed at baseline, after 9, and 18 weeks. The primary endpoint was global Quality of Life (QoL) at 9 weeks. For statistical analysis, a non-inferiority design was chosen applying linear mixed effects models for repeated measurements. The results were interpreted according to statistical significance and anchor-based, clinically relevant between-group minimally important differences (MID). A total of 160 patients aged (median (Interquartile range (IQR))) 78 years (76–81) were included. The QLQ-C30 questionnaire was completed by 150, 100, and 60 patients at baseline, at 9, and 18 weeks, respectively. The difference at 9 weeks in global QoL was 6.85 (95%CI-1.94; 15.65) and 7.37 (0.70; 14.05) in the physical functioning domain in favor of SOx exceeding the threshold for MID. At 18 weeks, the between-group MID in physical functioning was preserved. Dose-reduced combination chemotherapy may be recommended in vulnerable older patients with mCRC, rather than full-dose monotherapy.

TidsskriftAnnals of Oncology
Udgave nummerSuppl. 3
Sider (fra-til)208
StatusUdgivet - jun. 2021
BegivenhedESMO 23rd World Congress on Gastrointestinal Cancer - Virtual
Varighed: 30. jun. 20213. jul. 2021


KonferenceESMO 23rd World Congress on Gastrointestinal Cancer


Dyk ned i forskningsemnerne om 'Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study'. Sammen danner de et unikt fingeraftryk.
  • Nordic9-study

    Liposits, G. I., Pfeiffer, P., Winther, S. B., Ryg, J. & Skuladottir, H.


    Projekter: ProjektPh.d-projekt